Odonate, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improve and extend the lives of patients with cancer. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The firm is no longer in development of tesetax.
Follow-Up Questions
Odonate Inc のCEOは誰ですか？
Mr. Kevin Tang は Odonate Inc の Chairman of the Board で、2013 から在籍しています。
ODTC の株価パフォーマンスは？
ODTC の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Odonate Inc の主な事業テーマや業界は？
Odonate Inc は Pharmaceuticals 業界、セクターは Health Care に属しています。
